Nuvalent (NUVL) reported a Q3 net loss Tuesday of $1.28 per diluted share, widening from a loss of $0.59 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.93.
The clinical-stage biopharmaceutical company did not report any revenue for the quarter ended Sept. 30.